Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622197 | 0.88 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12623912 | 0.81 | HRH3 (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12626435 | 0.78 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12656063 | 0.74 | LMNA (0.43) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12656338 | 0.68 | LMNA (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12622139 | 0.65 | GFER (0.60) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12656195 | 0.65 | RAB9A (0.34) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12656286 | 0.65 | ALDH1A1 (0.40) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12626312 | 0.64 | ALDH1A1 (0.57) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12624106 | 0.63 | ALDH1A1 (0.56) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | ALDH1A1 2702/4885RAB9A 1724/4885NPC1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.